With the rapid advancement of technology, blood substitutes and alternate sources of therapeutic blood components are likely to become available, although not for a number of years. Within five to eight years, at least some plasma derivatives probably will be replaced by alternate sources using recombinant DNA technology; substitutes for RBCs and platelets will be much more difficult to develop. Availability of these products will have far-reaching effects on our health care system and it is probably not too soon to anticipate the effects and plan for the consequences.
|Number of pages||12|
|Publication status||Published - 1 Dec 1985|